ResMed Inc. (RMD)
Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength?
ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
RMD Stock Benefits From the Launch of NightOwl Across US
Resmed launches NightOwl, an FDA-cleared home sleep apnea test, in the United States to diagnose OSA at home.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is it Worth Adding ResMed Stock to Your Portfolio Now?
Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.
ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?
RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.
Here's Why ResMed (RMD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD)
ResMed (RMD) could produce exceptional returns because of its solid growth attributes.
Here's Why ResMed (RMD) Could be Great Choice for a Bottom Fisher
ResMed (RMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions
ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple Watch, underscores a significant growth opportunity, with millions still undiagnosed and untreated globally. Concerns over GLP-1 drugs reducing CPAP demand have diminished.
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
Stock Of The Day: Trading The Range In ResMed
ResMed Inc. RMD shares are consolidating on Monday. This follows Friday's decline of more than 8%.
